Skip to main content

Myfortic FDA Approval History

FDA Approved: Yes (First approved February 27, 2004)
Brand name: Myfortic
Generic name: mycophenolic acid
Dosage form: Tablets
Company: Novartis Pharma AG
Treatment for: Organ Transplant, Rejection Prophylaxis

Myfortic is an enteric-coated formulation of mycophenolic acid for use in combination with cyclosporine and corticosteroids to prevent organ rejection in kidney transplant patients.

Development timeline for Myfortic

Feb 27, 2004Approval Myfortic Novartis Pharma AG - Treatment for Prevention of Organ Rejection

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.